Verici Dx plc (AIM: VRCI)

Market Cap	10.31M
Revenue (ttm)	3.43M
Net Income (ttm)	-3.81M
Shares Out	242.54M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,383
Average Volume	895,039
Open	4.300
Previous Close	4.250
Day's Range	4.000 - 4.500
52-Week Range	2.270 - 13.000
Beta	1.73
RSI	54.26
Earnings Date	Apr 14, 2025

About Verici Dx

Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 14
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VRCI

Financial Performance

Financial numbers in USD